ES2123666T3 - Aplicacion de estriol para la preparacion de un sistema terapeutico transdermico para tratar la osteoporosis climaterica. - Google Patents

Aplicacion de estriol para la preparacion de un sistema terapeutico transdermico para tratar la osteoporosis climaterica.

Info

Publication number
ES2123666T3
ES2123666T3 ES93920566T ES93920566T ES2123666T3 ES 2123666 T3 ES2123666 T3 ES 2123666T3 ES 93920566 T ES93920566 T ES 93920566T ES 93920566 T ES93920566 T ES 93920566T ES 2123666 T3 ES2123666 T3 ES 2123666T3
Authority
ES
Spain
Prior art keywords
estriol
pct
osteoporosis
application
climate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920566T
Other languages
English (en)
Inventor
Walter Elger
Birgitt Schneider
Michael Oettel
Michael Ernst
Doris Huebler
Michael Dittgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENTEC
Entec Gesellschaft fuer Endokrinologische Technologie mbH
Original Assignee
ENTEC
Entec Gesellschaft fuer Endokrinologische Technologie mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENTEC, Entec Gesellschaft fuer Endokrinologische Technologie mbH filed Critical ENTEC
Application granted granted Critical
Publication of ES2123666T3 publication Critical patent/ES2123666T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE ESTRIOL COMO SUSTANCIA ACTIVA INDIVIDUAL PARA LA ELABORACION DE UN MEDICAMENTO TRANSDERMAL, QUE LIBERA CONTINUAMENTE LA SUSTANCIA ACTIVA PARA EL TRATAMIENTO DE OSTEOPOROSIS CLIMATERICA. DE ACUERDO CON LA INVENCION SE MUESTRA QUE EL ESTRIOL, QUE HASTA AHORA SE HA CONSIDERADO COMO NO EFECTIVO PARA EL TRATAMIENTO DE OSTEOPOROSIS CLIMATERICA, DESARROLLA UN EFECTO FUERTEMENTE ANTI-OSTEOPOROTICO CON APLICACION TRANSDERMAL CONTINUA.
ES93920566T 1992-03-21 1993-03-18 Aplicacion de estriol para la preparacion de un sistema terapeutico transdermico para tratar la osteoporosis climaterica. Expired - Lifetime ES2123666T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4209295 1992-03-21

Publications (1)

Publication Number Publication Date
ES2123666T3 true ES2123666T3 (es) 1999-01-16

Family

ID=6454737

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920566T Expired - Lifetime ES2123666T3 (es) 1992-03-21 1993-03-18 Aplicacion de estriol para la preparacion de un sistema terapeutico transdermico para tratar la osteoporosis climaterica.

Country Status (12)

Country Link
US (1) US5614213A (es)
EP (1) EP0630248B1 (es)
JP (1) JPH07504672A (es)
AT (1) ATE172118T1 (es)
AU (1) AU665997B2 (es)
CA (1) CA2131822C (es)
DE (1) DE59309063D1 (es)
DK (1) DK0630248T3 (es)
ES (1) ES2123666T3 (es)
HU (1) HU218290B (es)
RU (1) RU2119337C1 (es)
WO (1) WO1993018774A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19635883A1 (de) * 1996-09-04 1998-03-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination
DE19918644A1 (de) * 1999-04-16 2000-10-26 Jenapharm Gmbh Pharmazeutische Zusammensetzungen zur lokalen, intradermalen Applikation von Estrogenen
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
TW201946617A (zh) 2017-04-28 2019-12-16 日商日東電工股份有限公司 經皮吸收製劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3510555A1 (de) * 1985-03-21 1986-09-25 Schering AG, 1000 Berlin und 4709 Bergkamen Estriolester
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
ATE132751T1 (de) * 1988-10-27 1996-01-15 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
DE3910578A1 (de) * 1989-03-29 1990-10-04 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
DK0573604T3 (da) * 1991-02-26 1995-05-29 Procter & Gamble Pharma Fremgangsmåde til behandling af osteoporosis

Also Published As

Publication number Publication date
WO1993018774A1 (de) 1993-09-30
HU9402698D0 (en) 1994-11-28
HUT68213A (en) 1995-06-28
CA2131822A1 (en) 1993-09-22
RU2119337C1 (ru) 1998-09-27
EP0630248A1 (de) 1994-12-28
RU94045856A (ru) 1996-08-20
HU218290B (en) 2000-07-28
US5614213A (en) 1997-03-25
DK0630248T3 (da) 1999-06-23
CA2131822C (en) 2002-12-17
JPH07504672A (ja) 1995-05-25
AU3750093A (en) 1993-10-21
ATE172118T1 (de) 1998-10-15
DE59309063D1 (de) 1998-11-19
AU665997B2 (en) 1996-01-25
EP0630248B1 (de) 1998-10-14

Similar Documents

Publication Publication Date Title
BR9206632A (pt) Sistema de penetração na pele melhorado para melhorada liberação tópica de drogas
DE60239343D1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
BG104727A (en) Pharmaceutical composition of topiramate
MY129175A (en) Sertraline salts and sustained-release dosage forms of sertraline
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
MY111188A (en) Improvements in or relating to benzothiophenes.
ES2191475T3 (es) Conjugados de prostaglandina para el tratamiento o prevencion de enfermedades oseas.
ES2136723T3 (es) Utilizacion de n-aril-metilen-etilen-diamino-triacetatos, n-aril-metilen-imino-diacetatos o n,n'-diaril-metilen-etilen-diamino-acetatos contra el estres oxidante.
DE69713485D1 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
BR9708815A (pt) Composições farmacêuticas para prevenção e tratamento de desordens do sistema nervoso central.
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
DE69413829D1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
WO2004058235A3 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
ATE66149T1 (de) Pharmazeutische dosierungseinheit zur vorbeugung bzw. behandlung von klimakterischen beschwerden.
ES2123666T3 (es) Aplicacion de estriol para la preparacion de un sistema terapeutico transdermico para tratar la osteoporosis climaterica.
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
ES2184300T3 (es) Derivados de aminoacidos utiles para tratar el accidente vascular encefalico.
SE9303853L (sv) Användning av en inositoltrisfosfatester för beredning av läkemedel
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
DE68919673D1 (de) Verfahren zur behandlung und vorbeugung des verlustes von knochenmasse.
DE69312297T2 (de) Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs
FR2759586B1 (fr) Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol
ES2064382T3 (es) Agente para el tratamiento de la enfermedad de raynaud.
AR001226A1 (es) Métodos para el tratamiento de la osteoporosis utilizando fosofonatos activos y hormona paratiroidea

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 630248

Country of ref document: ES